Misplaced Pages

#472527

51-693: 4WA7 , 1D8D , 1D8E , 3GFT , 4DSN , 4DSO , 4EPR , 4EPT , 4EPV , 4EPW , 4EPX , 4EPY , 4L8G , 4LDJ , 4LPK , 4LRW , 4LUC , 4LV6 , 4LYF , 4LYH , 4LYJ , 4M1O , 4M1S , 4M1T , 4M1W , 4M1Y , 4M21 , 4M22 , 4NMM , 4OBE , 4PZY , 4PZZ , 4Q01 , 4Q02 , 4Q03 , 4QL3 , 4TQ9 , 4TQA , 4DST , 4DSU , 5F2E ,%%s 2MSC , 2MSD , 2MSE 3845 16653 ENSG00000133703 ENSMUSG00000030265 P01116 P32883 NM_004985 NM_033360 NM_001369786 NM_001369787 NM_021284 NP_004976 NP_203524 NP_001356715 NP_001356716 NP_004976.2 NP_001390173 NP_001390174 NP_001390175 KRAS ( Kirsten rat sarcoma virus)

102-529: A MEK inhibitor as a rational strategy for delaying or reversing drug resistance. KRAS gene can also be amplified in colorectal cancer and tumors harboring this genetic lesion are not responsive to EGFR inhibitors . Although KRAS amplification is infrequent in colorectal cancer, as of 2013 it was hypothesized to be responsible for precluding response to anti- EGFR treatment in some patients. As of 2015 amplification of wild-type Kras has also been observed in ovarian, gastric, uterine, and lung cancers. Whether

153-715: A KRAS mutation. There is one approved drug, sotorasib , that targets the KRAS G12C mutation, but only ~1% of PDACs have this mutation. Another KRAS inhibitor, MRTX1133 targets G12D mutation which is present in over 40% of PDACs is currently in clinical trials to treat solid tumors including pancreatic adenocarcinoma. In July 2009, the US Food and Drug Administration (FDA) updated the labels of two anti- EGFR monoclonal antibody drugs indicated for treatment of metastatic colorectal cancer, panitumumab (Vectibix) and cetuximab (Erbitux), to include information about KRAS mutations. In 2012,

204-481: A crucial finding in the field of cancer research, was discovered more than 40 years ago, and since then, the number of novel pathogenic oncogenes has increased steadily. The discovery of specific small-molecule inhibitors that specifically target the different oncogenic proteins and a comprehensive mechanistic analysis of the ways in which oncogenes dysregulate physiological signaling to cause different cancer types and developmental syndromes are potential future advances in

255-492: A gene therapy targeting KRAS G12D was recruiting patients, sponsored by the National Cancer Institute . In June 2022, a case report was published about a 71-year-old woman with metastatic pancreatic cancer after extensive treatment ( Whipple Surgery , radiation and multiple agent chemotherapy) who received a single infusion of her blood with engineered T cells with 2 genes encoding T cell receptors, directed to both

306-570: A molecular on/off switch, using protein dynamics . Once it is allosterically activated, it recruits and activates proteins necessary for the propagation of growth factors , as well as other cell signaling receptors like c-Raf and PI 3-kinase . KRAS upregulates the GLUT1 glucose transporter, thereby contributing to the Warburg effect in cancer cells. KRAS binds to GTP in its active state. It also possesses an intrinsic enzymatic activity which cleaves

357-539: A molecule of GTP. The K-Ras protein is turned off (inactivated) when it converts the GTP to GDP. When the protein is bound to GDP, it does not relay signals to the nucleus. The gene product of KRAS , the K-Ras protein, was first found as a p21 GTPase. Like other members of the ras subfamily of GTPases, the K-Ras protein is an early player in many signal transduction pathways. K-Ras is usually tethered to cell membranes because of

408-558: A number of drug candidates in preclinical stages of development targeting the KRAS G12D mutation. Mirati therapeutics has stated it was seeking investigational new drug (IND) approval in H1:2021 to start clinical trials. As of 2022 Revolution Medicines was exploring a small molecule therapy and reported anti-tumor activity in KRAS-G12D mutant tumor models. In 2021, the first clinical trial of

459-477: A patient is positive or negative for a mutation in the epidermal growth factor receptor (EGFR) will predict how patients will respond to certain EGFR antagonists such as erlotinib (Tarceva) or gefitinib (Iressa). Patients who harbor an EGFR mutation have a 60% response rate to erlotinib. However, the mutation of KRAS and EGFR are generally mutually exclusive. Lung cancer patients who are positive for KRAS mutation (and

510-549: A poor outcome in childhood neuroblastoma . Those children with amplification of N-myc, regardless of stage, will have shortened survival. Thus, therapeutic efforts are concentrated on intensifying treatment in this poor prognostic group. The theory of oncogenes was foreshadowed by the German biologist Theodor Boveri in his 1914 book Zur Frage der Entstehung Maligner Tumoren (Concerning the Origin of Malignant Tumors) in which he predicted

561-596: A proto-oncogene becomes a tumor-inducing agent, an oncogene. Examples of proto-oncogenes include RAS , WNT , MYC , ERK , and TRK . The MYC gene is implicated in Burkitt's lymphoma , which starts when a chromosomal translocation moves an enhancer sequence within the vicinity of the MYC gene. The MYC gene codes for widely used transcription factors. When the enhancer sequence is wrongly placed, these transcription factors are produced at much higher rates. Another example of an oncogene

SECTION 10

#1732854782473

612-425: A relatively small modification of its original function. There are three basic methods of activation: The expression of oncogenes can be regulated by microRNAs (miRNAs), small RNAs 21-25 nucleotides in length that control gene expression by downregulating them. Mutations in such microRNAs (known as oncomirs ) can lead to activation of oncogenes. Antisense messenger RNAs could theoretically be used to block

663-586: A response rate of up to 59% compared to those treated with chemotherapy alone. Patients with the KRAS wild-type gene also showed a 32% decreased risk of disease progression compared to patients receiving chemotherapy alone. As of 2012, it was known that emergence of KRAS mutations was a frequent driver of acquired resistance to cetuximab anti-EGFR therapy in colorectal cancers. The emergence of KRAS mutant clones can be detected non-invasively months before radiographic progression. It suggests to perform an early initiation of

714-555: A single nucleotide substitution, is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma , mucinous adenoma, ductal carcinoma of the pancreas and colorectal cancer . Several germline KRAS mutations have been found to be associated with Noonan syndrome and cardio-facio-cutaneous syndrome . Somatic KRAS mutations are found at high rates in leukemias , colorectal cancer, pancreatic cancer and lung cancer . The impact of KRAS mutations

765-483: A variety of intricate regulatory cascades within the cell. Genes known as proto-oncogenes are those that normally encourage cell growth and division in order to generate new cells or sustain the viability of pre-existing cells. When overexpressed, proto-oncogenes can be inadvertently activated (turned on), which changes them to oncogenes. There are numerous ways to activate (turn on) oncogenes in cells: Gene changes or mutations: A person's genetic "coding" may differ in

816-463: A very poor response to panitumumab (Vectibix) and cetuximab (Erbitux) therapy in colorectal cancer. As of 2008, the most reliable way to predict whether a colorectal cancer patient will respond to one of the EGFR-inhibiting drugs was to test for certain “activating” mutations in the gene that encodes KRAS, which occurs in 30%–50% of colorectal cancers. Studies show patients whose tumors express

867-783: A way that causes an oncogene to always be activated. These types of gene changes can develop spontaneously throughout the course of a person's life or they might be inherited from a parent when a transcription error occurs during cell division. Cells can frequently switch genes on or off via epigenetic mechanisms rather than actual genetic alterations. Alternately, different chemical compounds that can be linked to genetic material (DNA or RNA) may have an impact on which genes are active. An oncogene may sporadically become activated due to these epigenetic modifications. Visit Gene Alterations and Cancer to learn more about epigenetic alterations. Chromosomal rearrangement: Every living creature has chromosomes, which are substantial strands of DNA that contain

918-502: Is a gene that provides instructions for making a protein called K-Ras , a part of the RAS/MAPK pathway . The protein relays signals from outside the cell to the cell's nucleus. These signals instruct the cell to grow and divide ( proliferate ) or to mature and take on specialized functions ( differentiate ). It is called KRAS because it was first identified as a viral oncogene in the K irsten RA t S arcoma virus. The oncogene identified

969-817: Is a one-year internship for high school seniors in which they can immerse themselves into research and administrative management in a health care environment. Oncogene An oncogene is a gene that has the potential to cause cancer . In tumor cells , these genes are often mutated , or expressed at high levels. Most normal cells undergo a preprogrammed rapid cell death ( apoptosis ) if critical functions are altered and then malfunction. Activated oncogenes can cause those cells designated for apoptosis to survive and proliferate instead. Most oncogenes began as proto-oncogenes: normal genes involved in cell growth and proliferation or inhibition of apoptosis. If, through mutation, normal genes promoting cellular growth are up-regulated (gain-of-function mutation), they predispose

1020-411: Is heavily dependent on the order of mutations. Primary KRAS mutations generally lead to a self-limiting hyperplastic or borderline lesion, but if they occur after a previous APC mutation it often progresses to cancer. KRAS mutations are more commonly observed in cecal cancers than colorectal cancers located in any other places from ascending colon to rectum. As of 2006, KRAS mutation was predictive of

1071-405: Is important, because the optimal treatment for each form is different. Even in a particular disease, the identification of patients with good and poor prognostic potential is helpful, since more aggressive therapy may be needed to achieve a cure in the poor prognostic group. Oncogenes are prognostic markers in certain human cancers. N-myc amplification is an independent determinant in predicting

SECTION 20

#1732854782473

1122-650: Is the Bcr-Abl gene found on the Philadelphia chromosome , a piece of genetic material seen in Chronic Myelogenous Leukemia caused by the translocation of pieces from chromosomes 9 and 22. Bcr-Abl codes for a tyrosine kinase, which is constitutively active, leading to uncontrolled cell proliferation. (More information about the Philadelphia Chromosome below) The proto-oncogene can become an oncogene by

1173-434: Is to look for genes that are activated by mutations in human cancer cells or by chromosomal translocations that may indicate the presence of a gene that is crucial for cancer. Cancer patients are generally categorized according to clinical parameters in order to tailor their cancer therapy . For example, the separation of patients with acute leukemia into those with lymphocytic leukemia and those with myelocytic leukemia

1224-421: Is where GTP/GDP binds, but due to the extraordinarily high affinity of GTP/GDP for this site, it appeared unlikely as of 2018 that drug-like small molecule inhibitors could compete with GTP/GDP binding. Other than where GTP/GDP binds, there are no obvious high affinity binding sites for small molecules. One fairly frequent driver mutation is KRAS which is adjacent a shallow binding site. As of 2019, this allowed

1275-652: The Paul Ehrlich Institute in Frankfurt. In 1955, Kirsten moved to Chicago to pursue an internship and a residency . In 1956, he joined the Pathology Department at the University of Chicago . In 1960, he was granted American citizenship. He became an assistant professor in 1961, and — in the wake of his 1967 discovery of the sarcomavirus — a full professor in 1968. In 1972, he was promoted to head of

1326-565: The University of California, San Francisco demonstrated that oncogenes were activated proto-oncogenes as is found in many organisms, including humans. Bishop and Varmus were awarded the Nobel Prize in Physiology or Medicine in 1989 for their discovery of the cellular origin of retroviral oncogenes. Dr. Robert Weinberg is credited with discovering the first identified human oncogene in a human bladder cancer cell line. The molecular nature of

1377-404: The EGFR status would be wild type) have a low response rate to erlotinib or gefitinib estimated at 5% or less. Different types of data including mutation status and gene expression did not have a significant prognostic power. No correlation to survival was observed in 72% of all studies with KRAS sequencing performed in non-small cell lung cancer (NSCLC). However, KRAS mutations can not only affect

1428-463: The FDA cleared a genetic test by QIAGEN named therascreen KRAS test, designed to detect the presence of seven mutations in the KRAS gene in colorectal cancer cells. This test aids physicians in identifying patients with metastatic colorectal cancer for treatment with Erbitux. The presence of KRAS mutations in colorectal cancer tissue indicates that the patient may not benefit from treatment with Erbitux. If

1479-660: The G12D mutation and an HLA allele ( HLA-C *08:02). Her tumor regressed persistently. But another similarly treated patient died from the cancer. KRAS has been shown to interact with: Werner H. Kirsten Werner H. Kirsten was born in Leipzig in 1925. He attended the Universität Frankfurt am Main , graduating summa cum laude with an MD in 1953. He subsequently worked at the Senckenberg Institute of Pathology and

1530-619: The KRAS protein is occupied by glycine but in G12D it is occupied by aspartic acid. As of 2023, there are no commercial drug candidates targeting the KRAS G12D mutation in the clinical phase of development. A novel inhibitor finding strategy for mutated G12D KRAS molecules was described in. The KRAS mutations in the 12th residue position inhibit the bound of the regulatory GAP molecule to the mutated KRAS, causing uncontrolled cell growth. The novel strategy proposes finding small glue molecules, which attach

1581-443: The cell to cancer and are termed oncogenes . Usually, multiple oncogenes, along with mutated apoptotic or tumor suppressor genes , act in concert to cause cancer. Since the 1970s, dozens of oncogenes have been identified in human cancer. Many cancer drugs target the proteins encoded by oncogenes. Oncogenes are a physically and functionally diverse set of genes, and as a result, their protein products have pleiotropic effects on

KRAS - Misplaced Pages Continue

1632-620: The department of pathology. In 1986, he left the University and joined the National Cancer Institute as associate director of their facility in Frederick, Maryland . In 1988, he was promoted to director, a position he retained until his death. Kirsten was married to Inger Nielsen, with whom he had three sons, Christian, Olaf and Thomas. He died age 67 on December 24, 1992 in Hyde Park, Chicago . The Werner H. Kirsten Student Internship Program

1683-401: The development of electrophilic KRAS inhibitors that can form irreversible covalent bonds with nucleophilic sulfur atom of Cys-12 and hence selectively target KRAS and leave wild-type KRAS untouched. In 2021, the U.S. FDA approved one KRAS mutant covalent inhibitor , sotorasib (AMG 510, Amgen ) for the treatment of non-small cell lung cancer (NSCLC), the first KRAS inhibitor to reach

1734-404: The existence of oncogenes (Teilungsfoerdernde Chromosomen) that become amplified (im permanenten Übergewicht) during tumor development. Later on, the term "oncogene" was rediscovered in 1969 by National Cancer Institute scientists George Todaro and Robert Huebner . The first confirmed oncogene was discovered in 1970 and was termed SRC (pronounced "sarc" as it is short for sarcoma). SRC

1785-634: The field of cancer research. Investigating the quickly expanding field of oncogene molecular research, the goal of this special issue was to generate practical translational indicators that could be able to meet clinical needs. Genes that are considered crucial for cancer can be divided into two categories based on whether the harmful mutations in them result in function loss or gain. Gain-of-function mutations of proto-oncogenes drive cells to proliferate when they shouldn't, while loss-of-function mutations of tumor suppressor genes free cells from inhibitions that typically serve to control their numbers. The ability of

1836-470: The gene itself and the expression of the corresponding protein, but can also influence the expression of other downstream genes involved in crucial pathways regulating cell growth, differentiation and apoptosis. The different expression of these genes in KRAS -mutant tumors might have a more prominent role in affecting patient's clinical outcomes. A 2008 paper published in Cancer Research concluded that

1887-448: The genes for a cell. A chromosome's DNA sequence may alter each time a cell divides. This could cause a gene to be located near to a proto-oncogene that acts as an "on" switch, keeping it active even when it shouldn't. The cell can develop irregularly with the aid of this new oncogene. Gene duplication: If one cell has more copies of a gene than another, that cell may produce too much of a certain protein. The first human oncogene (HRAS),

1938-462: The in vivo administration of the compound oncrasin-1 "suppressed the growth of K-ras mutant human lung tumor xenografts by >70% and prolonged the survival of nude mice bearing these tumors, without causing detectable toxicity", and that the "results indicate that oncrasin-1 or its active analogues could be a novel class of anticancer agents which effectively kill K-Ras mutant cancer cells." Over 90% of pancreatic ductal adenocarcinomas (PDACs) have

1989-476: The market and enter clinical use. A second is adagrasib (MRTX-849, Mirati Therapeutics ) while JNJ-74699157 (also known as ARS-3248, Wellspring Biosciences / Janssen ) has received an investigational new drug (IND) approval to start clinical trials. An antisense oligonucleotide (ASO) targeting KRAS, AZD4785 ( AstraZeneca / Ionis Therapeutics ), completed a phase I study but in 2019 was discontinued from further development because of insufficient knockdown of

2040-419: The mutant genes, known as oncogenes, to steer a specific line of test cells toward malignant proliferation can occasionally be used to identify these later mutations, which have a dominating effect. Many of them were initially found to induce cancer in animals when they are introduced through viral vector infection, which carries genetic information from a prior host cell. Another method for identifying oncogenes

2091-454: The mutated KRAS to the GAP, prohibiting uncontrolled cell growth and restoring the normal function. For this goal a theoretical KRAS-GAP conformation was designed with a several Å gap between the molecules, and a high-throughput in silico docking was performed for finding gluing agents. As a proof of concept, two novel molecules were described with satisfying biological activity. As of 2021, there were

KRAS - Misplaced Pages Continue

2142-510: The mutated version of the KRAS gene will not respond to cetuximab or panitumumab. As of 2009, although presence of the wild-type (or normal) KRAS gene does not guarantee that these drugs will work, a number of large studies had shown that cetuximab had efficacy in mCRC patients with KRAS wild-type tumors. In the Phase III CRYSTAL study, published in 2009, patients with the wild-type KRAS gene treated with Erbitux plus chemotherapy showed

2193-551: The mutation leading to oncogenesis was subsequently isolated and characterized by the Spanish biochemist Mariano Barbacid and published in Nature in 1982. Dr. Barbacid spent the following months extending his research, eventually discovering that the oncogene was a mutated allele of HRAS and characterizing its activation mechanism. The resultant protein encoded by an oncogene is termed oncoprotein . Oncogenes play an important role in

2244-408: The presence of an isoprene group on its C-terminus . There are two protein products of the KRAS gene in mammalian cells that result from the use of alternative exon 4 (exon 4A and 4B respectively): K-Ras4A and K-Ras4B. These proteins have different structures in their C-terminal region and use different mechanisms to localize to cellular membranes, including the plasma membrane . KRAS acts as

2295-522: The regulation or synthesis of proteins linked to tumorigenic cell growth. Some oncoproteins are accepted and used as tumor markers. A proto-oncogene is a normal gene that could become an oncogene due to mutations or increased expression . Proto-oncogenes code for proteins that help to regulate the cell growth and differentiation . Proto-oncogenes are often involved in signal transduction and execution of mitogenic signals, usually through their protein products. Upon acquiring an activating mutation,

2346-550: The release of bound nucleotide (GDP). Subsequently, KRAS binds GTP present in the cytosol and the GEF is released from ras-GTP. Other members of the Ras family include: HRAS and NRAS . These proteins all are regulated in the same manner and appear to differ in their sites of action within the cell. This proto-oncogene is a Kirsten ras oncogene homolog from the mammalian Ras gene family. A single amino acid substitution, and in particular

2397-516: The target. A phase Ia/Ib dose escalation trial of the oral selective KRAS G12C inhibitor divarasib was published in 2023, where the drug was tested in non-small cell lung cancer, colorectal cancer, and other solid tumors with KRAS G12C mutations. It continues in phase I and II studies for several cancer types as of August 2023. The most common KRAS mutation is G12D which is estimated to be present in up to 37% pancreatic cancers and over 12% of colorectal cancers. Normally amino acid position 12 of

2448-544: The terminal phosphate of the nucleotide, converting it to GDP . Upon conversion of GTP to GDP, KRAS is deactivated. The rate of conversion is usually slow, but can be increased dramatically by an accessory protein of the GTPase-activating protein (GAP) class, for example RasGAP . In turn, KRAS can bind to proteins of the Guanine Nucleotide Exchange Factor (GEF) class (such as SOS1 ), which forces

2499-429: The test result indicates that the KRAS mutations are absent in the colorectal cancer cells, then the patient may be considered for treatment with Erbitux. As of 2014, driver mutations in KRAS were known to underlie the pathogenesis of up to 20% of human cancers. Hence KRAS is an attractive drug target, but as of 2018 lack of obvious binding sites had hindered pharmaceutical development. One potential drug interaction site

2550-440: Was derived from a cellular genome, so KRAS , when found in a cellular genome, is called a proto-oncogene . The K-Ras protein is a GTPase , a class of enzymes which convert the nucleotide guanosine triphosphate (GTP) into guanosine diphosphate (GDP) . In this way the K-Ras protein acts like a switch that is turned on and off by the GTP and GDP molecules. To transmit signals, it must be turned on by attaching (binding) to

2601-452: Was first discovered as an oncogene in a chicken retrovirus . Experiments performed by Dr. G. Steve Martin of the University of California, Berkeley demonstrated that SRC was indeed the gene of the virus that acted as an oncogene upon infection. The first nucleotide sequence of v-Src was sequenced in 1980 by A.P. Czernilofsky et al. In 1976, Drs. Dominique Stéhelin  [ fr ] , J. Michael Bishop and Harold E. Varmus of

SECTION 50

#1732854782473
#472527